Home News Page 3


Forest Laboratories and Glenmark Pharmaceuticals Sign Development Agreement for Worldwide Collaboration on Novel Agents...

Mumbai, December 24, 2012: Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), a leading Indian multinational pharmaceutical company,  announced today  that it has entered into an agreement with Forest Laboratories, Inc(NYSE: FRX), an international health care leader, on a collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.   Glenmark has identified clinical candidates and is currently conducting pre-clinical studies and other development activities required to support the initiation of first-in-human dosing.